Biotech | November 30, 2021
Thermo Fisher Scientific’s new CRISPR Genome editing protein
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The company has has 10 existing labs in India
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
The campaign aims to increase awareness about Tuberculosis as a curable disease and promote early diagnosis.
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Owkin builds best-in-class predictive biomedical AI models and robust data sets
Subscribe To Our Newsletter & Stay Updated
